BioLab Holdings Rebrands as EmeraNova

The Phoenix-based firm is expanding its medical focus beyond chronic wound care.

Updated on Oct. 15, 2026 in Healthcare

Isometric editorial illustration showing a clean, geometric medical research building architecture, representing a corporate transition in biotechnology. — Medical technology firm BioLab Holdings has rebranded as EmeraNova, pivoting its strategy to expand into acute surgical and sports medicine markets. AI Illustration. Upload story photo >

BioLab Holdings has officially launched a new corporate identity, rebranding as EmeraNova. The company aims to leverage this transition to expand its clinical applications and enter new care settings, such as hospital outpatient departments.

Why it matters

The rebrand signals a strategic move to broaden the company reach beyond chronic wound care into acute care, surgery, and sports medicine. This shift aligns with the firm's goal to accelerate the path of promising technologies into clinical practice.

EmeraNova completed four clinical trials and three peer-reviewed studies in 2026. Its proprietary toolbox model for tissue management consists of eight distinct stages.

The players

EmeraNova

This Phoenix-based healthcare company, formerly known as BioLab Holdings, specializes in amniotic membrane technology and tissue-related medical research.

BLS Labs, LLC

This entity maintains AATB accreditation and serves as a core component of the company's research and development infrastructure.

The details

EmeraNova, which maintains an extensive amniotic membrane product portfolio, is scaling its research capabilities across vascular care and aesthetics. The company intends to extend its innovations globally by pursuing new commercialization partnerships.

BioLab Holdings announced the launch of EmeraNova on October 15, 2026.
The firm completed four clinical trials and three studies throughout 2026.
EmeraNova will showcase its brand at the Symposium for Advanced Wound Care in Las Vegas from October 16-18, 2026.

Market Landscape

The rebrand follows a pattern of corporate consolidation and specialization within the regenerative medicine sector. By establishing the EmeraNova name, the company aims to sharpen its competitive edge against established medical technology firms in global outpatient and hospital markets.

Patients and healthcare providers can expect a broader range of applications for the firm's amniotic membrane products in the near future. This corporate expansion may eventually lead to increased availability of these technologies within acute care settings and hospital outpatient departments.

The takeaway

The transition to EmeraNova reflects a strategic pivot toward broader clinical utility in surgical and sports medicine settings. Interested parties can view the company's latest developments at booth 241 during the upcoming symposium in Las Vegas.